IGC Pharma, Inc.

Name: IGC Pharma, Inc. key financials
Creator: Listed

IGCNYSECIK 1326205HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2027$265.0kThree months to Jun 30, 2026, from the 10-Q filed Aug 14, 2026.

Latest quarter: Q2 FY2027

Three months to Jun 30, 2026, against the same quarter a year earlier.

Revenue$265.0k−19.2% on a year earlier
Gross margin18.1%−28.8 pts on a year earlier
Operating margin−1050.6%−469.8 pts on a year earlier
Net margin−1107.9%−620.4 pts on a year earlier
Diluted EPS−$0.03−50.0% on a year earlier
Free cash flow−$1.4m+4.2% on a year earlier

Last eight quarters

Full statements

Revenue$265.0kGross margin 18.1%

Diluted EPS−$0.03, Q2 FY2027

Free cash flow−$1.4m, Q2 FY2027

IGC Pharma, Inc., key figures for the last eight quarters
Line item	Unit	Q2 FY20252024-09-30	Q3 FY20252024-12-31	Q4 FY20252025-03-31	Q1 FY20262025-06-30	Q2 FY20262025-09-30	Q3 FY20262025-12-31	Q1 FY20262026-03-31	Q2 FY20272026-06-30
Revenue	$k	412	257	330	328	191	350	317	265
Gross margin	%	48.1%	40.5%	46.7%	47.0%	51.8%	12.6%	17.4%	18.1%
Operating margin	%	(427.2%)	(730.7%)	(428.2%)	(580.8%)	(1517.8%)	(840.3%)	(775.4%)	(1050.6%)
Net margin	%	(416.7%)	(711.7%)	(363.0%)	(487.5%)	(953.4%)	(207.4%)	(757.7%)	(1107.9%)
Diluted EPS	$ per share	(0.02)	(0.02)	(0.02)	(0.02)	(0.02)	not reported (Diluted EPS not reported)	(0.02)	(0.03)
Free cash flow	$k	(1,025)	(1,344)	(748)	(1,415)	(2,119)	(1,235)	(1,224)	(1,355)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.3mGross margin 48.7%

Diluted EPS−$0.09, FY2025

Free cash flow−$4.9m, FY2025

IGC Pharma, Inc., key figures for the last five fiscal years
Line item	Unit	FY20212021-03-31	FY20222022-03-31	FY20232023-03-31	FY20242024-03-31	FY20252025-03-31
Revenue	$m	0.9	0.4	0.9	1.3	1.3
Gross margin	%	12.6%	48.9%	48.5%	54.5%	48.7%
Operating margin	%	(971.5%)	(3886.1%)	(1270.1%)	(728.5%)	(585.8%)
Net margin	%	(981.2%)	(3782.4%)	(1263.0%)	(966.5%)	(560.3%)
Diluted EPS	$ per share	(0.21)	not reported (Diluted EPS not reported)	not reported (Diluted EPS not reported)	(0.22)	(0.09)
Free cash flow	$m	(12.3)	(7.7)	(7.4)	(5.3)	(4.9)

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding IGC Pharma, Inc.
Fund	Quarter ended	Reported value	Shares	Change on the quarter before
GEODE CAPITAL MANAGEMENT, LLC	2026-06-30	$239.2k	879,394	Reduced−163,990
VANGUARD CAPITAL MANAGEMENT LLC	2026-06-30	$221.7k	814,914	Added+96,478
BlackRock, Inc.	2026-06-30	$191.4k	703,798	Unchanged
AdvisorShares Investments LLC	2026-06-30	$184.5k	678,480	New+678,480
CITADEL ADVISORS LLC	2026-06-30	$119.0k	437,317	New+437,317
VANGUARD FIDUCIARY TRUST CO	2026-06-30	$114.1k	419,413	Added+3,525
RENAISSANCE TECHNOLOGIES LLC	2026-06-30	$78.0k	286,608	Reduced−197,367
STATE STREET CORP	2026-06-30	$54.6k	200,799	Unchanged
NORTHERN TRUST CORP	2026-06-30	$46.3k	170,274	Added+56,867
LAWOOD & CO	2026-06-30	$20.4k	75,000	Unchanged

Recent filings

All 638 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

IGC Pharma, Inc., recent filings
Filed	Form	What it is	Accession number
2026-10-2200:32 ET	DEF 14A	Proxy statementPeriod 2026-12-02	0001185185-26-004896
2026-08-1420:01 ET	10-Q	Quarterly reportPeriod 2026-06-30	0001185185-26-003544
2026-07-1422:11 ET	8-K	7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits	0001185185-26-002922
2026-07-0620:02 ET	8-K	1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits	0001185185-26-002808
2026-06-0820:03 ET	8-K	1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits	0001185185-26-002410
2026-05-1520:02 ET	10-Q	Quarterly reportPeriod 2026-03-31	0001185185-26-001885
2026-04-2020:01 ET	8-K	1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits	0001185185-26-001437
2026-03-3021:43 ET	8-K	8.01 Other events; 9.01 Financial statements and exhibits	0001185185-26-001146
2026-03-1222:19 ET	8-K	1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits	0001185185-26-000846
2026-01-0623:11 ET	8-K	1.01 Entry into a material agreement; 9.01 Financial statements and exhibits	0001185185-26-000032

Latest annual report

Form 10-K for the fiscal year ended Mar 31, 2025Filed Jun 27, 2025. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK: 1326205
Tickers: IGC
Exchange: NYSE
SIC code: 2834 Pharmaceutical Preparations
Sector: Healthcare
Fiscal year ends: Dec 31
Incorporated in: MD
Filer category: Non-accelerated filer<br>Smaller reporting company
Former names: India Globalization Capital, Inc. (to 2023-03-21)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. Listed shows no prices and gives no investment advice.